Cystic fibrosis is a progressive, genetic disorder that causes damage to the respiratory system and also causes chronic digestive system problems. Degree of severity differs from individual to individual. Patients suffering from cystic fibrosis have complication such as difficulty in digestion of fats and proteins. Symptoms associated with cystic fibrosis includes sinus infection, frequent lung infections including pneumonia or bronchitis, cystic fibrosis related diabetes and progressive lung damage. Cystic fibrosis can be developed by people from both genders, races and ethnic groups. However, the incidence of cystic fibrosis is common among Caucasians of Northern European descent, Latinos, American Indians.
Global cystic fibrosis therapeutics market is segmented based of drug class, route of administration, and regions. Factors driving demand for global cystic fibrosis therapeutics market includes increasing in prevalence of cystic fibrosis and development of innovative therapies for effective and efficient treatment. However, high investment incurred in research and development and cost of the treatment are factors limiting the growth of cystic fibrosis therapeutics market.
Drug class segment includes Pancreatic enzyme supplements, Mucolytics, Bronchodilators, and CFTR modulators. The CFTR modulators is expected to witness rapid growth over the forecast period owing to increasing number of approvals.
Route of Administration segment includes oral drugs and Inhaled drugs. The inhaled drugs contribute to the major market share owing to ease of administration of the drug. Moreover, it reduces side effects of medicine.
Do Inquiry of the Report Here: https://marketresearch.biz/report/cystic-fibrosis-therapeutics-market/#inquiry
North America contributes the major market share as compared to other regions. This is attributed to well-developed healthcare infrastructure and availability of skilled medical personnel. Furthermore, Revenue from the market in Asia Pacific is expected to continue to grow significantly over the forecast period.
Some prominent players in the global cystic fibrosis therapeutics market are AbbVie Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc. Alcresta Therapeutics Inc., Allergan Plc., AstraZeneca Plc. and Alaxia.